Other Consolidated Financial Statement Detail - Other Income (Expense), Net (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Apr. 30, 2022	Jun. 30, 2018	Feb. 29, 2012
Collaborative arrangements and non-collaborative arrangement transactions
Interest income		$ (67.6)	$ (276.5)	$ (89.3)
Interest expense		250.3	246.9	246.6
(Gains) losses on investments, net		100.4	291.2	277.3
Foreign exchange (gains) losses, net		30.9	50.4	35.5
Gain on sale of equity interest in Samsung Bioepis		0.0	0.0	(1,505.4)
Litigation settlement agreement and settlement fees	$ 900.0	0.0	0.0	917.0
Other, net		29.6	3.5	10.1
Other (income) expense, net		$ 343.6	$ 315.5	$ (108.2)
Samsung Bioepis
Collaborative arrangements and non-collaborative arrangement transactions
Ownership percentage	49.90%				49.90%	49.90%	15.00%